Tracer-based metabolomics: concepts and practices.

Tracer-based metabolomics is a systems biology tool that combines advances in tracer methodology for physiological studies, high throughput "-omics" technologies and constraint based modeling of metabolic networks. It is different from the commonly known metabolomics or metabonomics in that it is a targeted approach based on a metabolic network model in cells. Because of its complexity, it is the least understood among the various "-omics." In this review, the development of concepts and practices of tracer-based metabolomics is traced from the early application of radioactive isotopes in metabolic studies to the recent application of stable isotopes and isotopomer analysis using mass spectrometry; and from the modeling of biochemical reactions using flux analysis to the recent theoretical formulation of the constraint based modeling. How these newer experimental methods and concepts of constraint-based modeling approaches can be applied to metabolic studies is illustrated by examples of studies in determining metabolic responses of cells to pharmacological agents and nutrient environment changes.

[1]  W. Lee.  Characterizing phenotype with tracer based metabolomics , 2006, Metabolomics.

[2]  Marta Cascante,et al.  Dynamic profiling of the glucose metabolic network in fasted rat hepatocytes using [1,2-13C2]glucose. , 2004, The Biochemical journal.

[3]  Robert R. Wolfe,et al.  Radioactive and Stable Isotope Tracers in Biomedicine: Principles and Practice of Kinetic Analysis , 1992 .

[4]  Marta Cascante,et al.  K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. , 2005, Cancer research.

[5]  W. Lee,et al.  Application of mass isotopomer analysis for determination of pathways of glycogen synthesis. , 1991, The American journal of physiology.

[6]  Vitaly A. Selivanov,et al.  An optimized algorithm for flux estimation from isotopomer distribution in glucose metabolites , 2004, Bioinform..

[7]  L. Boros,et al.  A Metabolic Hypothesis of Cell Growth and Death in Pancreatic Cancer , 2002, Pancreas.

[8]  B. Palsson,et al.  The underlying pathway structure of biochemical reaction networks. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Jason A. Papin,et al.  Metabolic pathways in the post-genome era. , 2003, Trends in biochemical sciences.

[10]  Elaine Holmes,et al.  The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. , 2005, Pharmacogenomics.

[11]  Marta Cascante,et al.  Metabolic profiling of cell growth and death in cancer: applications in drug discovery. , 2002, Drug discovery today.

[12]  Vitaly A. Selivanov,et al.  Software for dynamic analysis of tracer-based metabolomic data: estimation of metabolic fluxes and their statistical analysis , 2006, Bioinform..

[13]  B. Palsson,et al.  Theory for the systemic definition of metabolic pathways and their use in interpreting metabolic function from a pathway-oriented perspective. , 2000, Journal of theoretical biology.

[14]  Vitaly A. Selivanov,et al.  Rapid simulation and analysis of isotopomer distributions using constraints based on enzyme mechanisms: an example from HT29 cancer cells , 2005, Bioinform..

[15]  P. Wals,et al.  Studies of glycogen synthesis and the Krebs cycle by mass isotopomer analysis with [U-13C]glucose in rats. , 1989, The Journal of biological chemistry.

[16]  W. Lee,et al.  Fatty Acid Transport and Utilization for the Developing Brain , 1998, Journal of neurochemistry.

[17]  P. Wals,et al.  Determination of pathways of glycogen synthesis and the dilution of the three-carbon pool with [U-13C]glucose. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Y. Yen,et al.  Inhibition of protein phosphorylation in MIA pancreatic cancer cells: confluence of metabolic and signaling pathways. , 2010, Journal of proteome research.

[19]  Henrik Antti,et al.  Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. , 2003, Toxicology and applied pharmacology.

[20]  John C. Lindon,et al.  Metabonomics Techniques and Applications to Pharmaceutical Research & Development , 2006, Pharmaceutical Research.

[21]  Marta Cascante,et al.  Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer , 2006, International journal of cancer.

[22]  D. Schoeller,et al.  In vivo measurement of fatty acids and cholesterol synthesis using D2O and mass isotopomer analysis. , 1994, The American journal of physiology.

[23]  B. Landau,et al.  Interpretation of isotopomer patterns in tracing glycogen synthesis and glucose recycling using [13C6]glucose. , 1990, The American journal of physiology.

[24]  S. Bassilian,et al.  Mass isotopomer study of glutamine oxidation and synthesis in primary culture of astrocytes. , 1996, Developmental neuroscience.

[25]  M. Cascante,et al.  Transforming growth factor beta2 promotes glucose carbon incorporation into nucleic acid ribose through the nonoxidative pentose cycle in lung epithelial carcinoma cells. , 2000, Cancer research.

[26]  Thomas Szyperski,et al.  Amino acid biosynthesis and metabolic flux profiling of Pichia pastoris. , 2004, European journal of biochemistry.

[27]  B. Palsson,et al.  Combining pathway analysis with flux balance analysis for the comprehensive study of metabolic systems. , 2000, Biotechnology and bioengineering.

[28]  W. Lee,et al.  Mass isotopomer analysis: theoretical and practical considerations. , 1991, Biological mass spectrometry.

[29]  S. Bassilian,et al.  In vivo study of the biosynthesis of long-chain fatty acids using deuterated water. , 1995, The American journal of physiology.

[30]  P. Wals,et al.  Isotopomer studies of gluconeogenesis and the Krebs cycle with 13C-labeled lactate. , 1993, The Journal of biological chemistry.

[31]  U. Sauer,et al.  Central carbon metabolism of Saccharomyces cerevisiae explored by biosynthetic fractional (13)C labeling of common amino acids. , 2001, European journal of biochemistry.

[32]  B. Palsson,et al.  Characterizing the metabolic phenotype: A phenotype phase plane analysis , 2002, Biotechnology and bioengineering.

[33]  R. Heinrich,et al.  Metabolic Pathway Analysis: Basic Concepts and Scientific Applications in the Post‐genomic Era , 1999, Biotechnology progress.

[34]  Royston Goodacre,et al.  Metabolomics: Current technologies and future trends , 2006, Proteomics.

[35]  E. Go,et al.  Database Resources in Metabolomics: An Overview , 2010, Journal of Neuroimmune Pharmacology.

[36]  W. Lee.  Appendix. Analysis of tricarboxylic acid cycle using mass isotopomer ratios. , 1993, The Journal of biological chemistry.

[37]  B. Hammock,et al.  Mass spectrometry-based metabolomics. , 2007, Mass spectrometry reviews.

[38]  J. Lindon,et al.  Metabonomics: a platform for studying drug toxicity and gene function , 2002, Nature Reviews Drug Discovery.

[39]  L. Boros,et al.  PNU-91325 increases fatty acid synthesis from glucose and mitochondrial long chain fatty acid degradation: a comparative tracer-based metabolomics study with rosiglitazone and pioglitazone in HepG2 cells , 2006, Metabolomics.

[40]  E. Bergner,et al.  Mass isotopomer pattern and precursor-product relationship. , 1992, Biological mass spectrometry.

[41]  Marta Cascante,et al.  Use of metabolic pathway flux information in targeted cancer drug design , 2004 .

[42]  M. Cascante,et al.  Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation , 2010, Metabolomics.

[43]  Jason A. Papin,et al.  Extreme pathway lengths and reaction participation in genome-scale metabolic networks. , 2002, Genome research.

[44]  L. Boros,et al.  Development of Tracer-Based Metabolomics and its Implications for the Pharmaceutical Industry , 2007, International Journal of Pharmaceutical Medicine.

[45]  M. Cascante,et al.  Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA). , 2003, Blood.

[46]  D. Kell,et al.  A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations , 2001, Nature Biotechnology.

[47]  Jason A. Papin,et al.  Genome-scale microbial in silico models: the constraints-based approach. , 2003, Trends in biotechnology.

[48]  F. Regnier,et al.  Differential metabolomics using stable isotope labeling and two-dimensional gas chromatography with time-of-flight mass spectrometry. , 2008, Analytical chemistry.

[49]  David S. Wishart,et al.  Current Progress in computational metabolomics , 2007, Briefings Bioinform..

[50]  David S. Wishart,et al.  HMDB: a knowledgebase for the human metabolome , 2008, Nucleic Acids Res..

[51]  J. P. Rife,et al.  The role of serine hydroxymethyltransferase isozymes in one-carbon metabolism in MCF-7 cells as determined by (13)C NMR. , 2001, Archives of biochemistry and biophysics.

[52]  D. Kell.  Systems biology, metabolic modelling and metabolomics in drug discovery and development. , 2006, Drug discovery today.

[53]  William J. Griffiths,et al.  Mass spectrometry: from proteomics to metabolomics and lipidomics. , 2009, Chemical Society reviews.

[54]  J. McGarry,et al.  The glucose paradox. Is glucose a substrate for liver metabolism? , 1984, The Journal of clinical investigation.

[55]  V. Go,et al.  Nutrient-gene interaction: tracer-based metabolomics. , 2005, The Journal of nutrition.

[56]  M. Orešič,et al.  Data processing for mass spectrometry-based metabolomics. , 2007, Journal of chromatography. A.